William Cross
Leeds Teaching Hospitals NHS Trust(GB)St James's University Hospital(GB)University of Reading(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Bladder and Urothelial Cancer Treatments, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial(2015)1,944 cited
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,235 cited
- → Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial(2019)395 cited
- → Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial(2020)389 cited
- → Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol